Abstract 6390: Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer

医学 化疗 生物标志物 安慰剂 阶段(地层学) 癌症 内科学 肿瘤科 肺癌 病理 生物 生物化学 古生物学 替代医学
作者
Ying Cheng,Liang Han,Lin Wu,Jun Chen,Hongmei Sun,Guilan Wen,Yinghua Ji,Anastasia Zimina,Jianhua Shi,Zhijie Pan,Jinsheng Shi,Xicheng Wang,Fang Yang,Xinyi Yang,M. Chen,Shiqi Zhong,Qingyu Wang,Jing Li,Jiancheng Cheng,Ling Chen,Yongqiang Shan,Junwu Zhu
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 6390-6390 被引量:1
标识
DOI:10.1158/1538-7445.am2024-6390
摘要

Abstract Background First-line serplulimab plus chemotherapy (chemo) significantly improved OS compared with chemo alone for patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase 3 ASTRUM-005 study. In this exploratory biomarker analysis, we retrospectively evaluated the association of proteome signature, genetic mutations, and hematological indices with efficacy. Methods: Serum proteomics data were generated via Olink® Explore 3072 platform for 168 patients (training: 80; validation: 88). Genetic mutations were assessed by Med1CDxTM panel for 305 patients. Baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels were analyzed in all 585 patients. Clinical data cutoff date was June 13, 2022. Results: From Olink data, we generated a 15-protein signature. Results in the validation cohort are shown in the table below. Patients with upper signature score derived higher PFS (7.89 vs 4.17 mo, HR 0.37) and OS (17.18 vs 9.74 mo, HR 0.27) benefit from adding serplulimab, than those with lower signature score (PFS: 4.40 vs 4.34 mo, HR 0.68; OS: 9.05 vs 9.22 mo, HR 0.76). Patients with mutations in RB1 or NOTCH pathway had better tumor responses to the treatment of serplulimab-chemo (ORR: 80% and 86%, respectively) when compared to patients without mutations in RB1 or NOTCH pathway (ORR: 58% and 68%). Patients with NLR ≤4.6, PLR ≤338.3, and LDH ≤ upper limit of normal tended to have longer PFS and OS in both treatment groups; NLR and LDH were further proven to be independent prognostic biomarkers in multivariate regression (P = 0.002 and P <0.001, respectively). Conclusions: We found a 15-protein signature showing predictive power for serplulimab-chemo treatment; RB1 or NOTCH pathway mutations were enriched in serplulimab-chemo responders; baseline NLR and LDH were independent prognostic biomarkers for ES-SCLC. The above findings warrant further investigations. Serplulimab-chemo (n=48) Placebo-chemo (n=40) HR (95% CI) P Upper signature score, n 31 34 Median PFS (95% CI), months 7.89 (1.27, 10.74) 4.17 (2.96, 4.34) 0.37 (0.21, 0.66) <0.001 Median OS (95% CI), months 17.18 (11.01, NE) 9.74 (6.90, 12.65) 0.27 (0.15, 0.50) <0.001 Lower signature score, n 17 6 Median PFS (95% CI), months 4.40 (3.61, 5.75) 4.34 (2.66, NE) 0.68 (0.23, 2.02) 0.488 Median OS (95% CI), months 9.05 (6.67, 11.73) 9.22 (4.53, NE) 0.76 (0.29, 1.98) 0.570 Citation Format: Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Fang Yang, Xinyi Yang, Mengkai Chen, Shiqi Zhong, Qingyu Wang, Jing Li, Jiancheng Cheng, Chen Ling, Yongqiang Shan, Jun Zhu, The ASTRUM-005 Study Group. Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6390.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CNYDNZB完成签到 ,获得积分10
刚刚
Harlotte完成签到 ,获得积分10
7秒前
fjmelite完成签到 ,获得积分10
7秒前
CYYDNDB完成签到 ,获得积分10
8秒前
Serein完成签到,获得积分10
11秒前
Jasper应助阔达的棒棒糖采纳,获得10
11秒前
勤劳的老九应助轩辕唯雪采纳,获得10
13秒前
水晶李完成签到 ,获得积分10
16秒前
Bismarck发布了新的文献求助10
22秒前
25秒前
smottom应助轩辕唯雪采纳,获得20
29秒前
晨许沫光发布了新的文献求助10
30秒前
所所应助玄学小生采纳,获得10
32秒前
研友_Ljqal8完成签到,获得积分10
44秒前
JACK完成签到,获得积分10
44秒前
清修完成签到,获得积分10
45秒前
健忘的晓小完成签到 ,获得积分10
45秒前
47秒前
犹豫野狼完成签到 ,获得积分10
48秒前
48秒前
传奇3应助U9A采纳,获得10
54秒前
晨许沫光完成签到 ,获得积分10
57秒前
柒八染完成签到 ,获得积分10
1分钟前
1分钟前
Bryan应助疯狂的向日葵采纳,获得10
1分钟前
酷酷的涵蕾完成签到 ,获得积分10
1分钟前
1分钟前
朱比特完成签到,获得积分10
1分钟前
晟sheng完成签到 ,获得积分10
1分钟前
苹果摇伽完成签到,获得积分10
1分钟前
弄香完成签到,获得积分10
1分钟前
Moonchild完成签到 ,获得积分10
1分钟前
坦率雪枫完成签到 ,获得积分10
1分钟前
Bismarck完成签到,获得积分10
1分钟前
现实的大白完成签到 ,获得积分10
1分钟前
1分钟前
唐唐完成签到 ,获得积分10
1分钟前
1分钟前
Leo完成签到 ,获得积分10
1分钟前
阔达的棒棒糖完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167340
捐赠科研通 3248714
什么是DOI,文献DOI怎么找? 1794453
邀请新用户注册赠送积分活动 875065
科研通“疑难数据库(出版商)”最低求助积分说明 804664